ATI -1701Appili was granted a pre-IND meeting with the FDA to discuss ATI-1701’s regulatory, CMC, toxicology, and Phase 1 strategies and expects to receive feedback in early 2024. The goal of the ATI-1701 program is to evaluate the immunogenicity, efficacy, and safety of the ATI-1701 vaccine and ultimately submit a Biological License Application.
A fast track approval by the FDA can happen at the end of 2024. The goverment funding speaks for itself.
At this PPS I see low risk but a massive upside during next year. Buy early and keep patience. This is my strategy for success.